文献速递肝病消化道肿瘤与早癌

丙型肝炎病毒清除后肝病残余风险

Residual risk of liver disease after hepatitis C virus eradication.
PubMed 文献 · J Hepatol · 2020-12-01

直接抗病毒药物治疗丙型肝炎安全高效,可使绝大多数患者获得持续病毒学应答(SVR)。SVR多永久且显著降低肝病发病率与死亡率,但部分患者仍面临进行性肝损伤的重大风险,可能导致肝失代偿、肝细胞癌和死亡。本综述讨论了获得SVR后残余肝病的重要特征。

要点

  • 直接抗病毒药物治疗丙肝安全高效,绝大多数患者可获得SVR。
  • SVR多永久且显著降低肝病发病率与死亡率。
  • 部分SVR患者仍面临进行性肝损伤风险,可致肝失代偿、肝癌和死亡。

核心结论

  • 尽管SVR显著降低肝病发病率与死亡率,部分患者仍存在进行性肝损伤的重大风险,可导致肝失代偿、肝细胞癌和死亡。

研究设计与样本

  • 本文为简明综述,讨论慢性丙型肝炎患者经抗病毒治疗获得SVR后残余肝病的重要特征。

主要发现

  • 直接抗病毒药物治疗丙型肝炎安全且高度有效,使绝大多数患者获得SVR。
  • SVR多为永久性,并与肝病发病率与死亡率的显著降低相关。
  • 部分获得SVR的患者仍可能面临进行性肝损伤的重大风险,潜在导致肝失代偿、肝细胞癌和死亡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment of hepatitis C with direct-acting antivirals is safe and highly efficacious, resulting in viral clearance (sustained virological response [SVR]) in the vast majority of patients. Although SVR is mostly permanent and associated with a significant reduction of liver morbidity and mortality, some patients may still suffer from a major risk of progressive liver damage, potentially leading to severe complications - including liver decompensation, hepatocellular carcinoma and death. This concise review discusses some of the most important features of residual liver disease in patients with chronic hepatitis C who have achieved SVR after antiviral therapy.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Negro F. Residual risk of liver disease after hepatitis C virus eradication. J Hepatol. 2020. PMID: 33276027. doi:10.1016/j.jhep.2020.11.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。